ZDA
ASND icon

Zweig-DiMenna Associates’s Ascendis Pharma A/S ASND Stock Holding History

Zweig-DiMenna Associates’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,500
Closed -$3.31M – 66
2025
Q4 		$3.31M Buy
+15,500
New +$3.2M 0.21% 90

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Zweig-DiMenna Associates's ASND Position: Q1 2026 in Review

Zweig-DiMenna Associates sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 15,500 shares — an estimated $3.31M sold.

Zweig-DiMenna Associates first reported a position in ASND in Q4 2025 and held it in 1 quarter. The position peaked at $3.31M in Q4 2025. 274 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

  • Zweig-DiMenna Associates reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 15,500 Ascendis Pharma A/S shares in Q1 2026, an estimated $3.31M.
  • Zweig-DiMenna Associates first reported a position in Ascendis Pharma A/S in Q4 2025 and held it in 1 quarter.
  • Zweig-DiMenna Associates's Ascendis Pharma A/S position peaked at $3.31M in Q4 2025.
  • 274 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Zweig-DiMenna Associates's 13F filing for Q1 2026, filed 5 May 2026.